<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>Vote</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>OV-D (1 of 2)</td>
<td>Internal request: Consider adding liposomal doxorubicin/bevacizumab to the list of preferred recurrence therapies for platinum-resistant disease.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider adding paclitaxel (weekly)/bevacizumab to the list of preferred recurrence therapies for platinum-resistant disease.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider adding topotecan/bevacizumab to the list of preferred recurrence therapies for platinum-resistant disease.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>External Request: Submission by Genentech Inc. to consider recently presented data from the ICON7 and AURELIA trials for updates.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Based on the data in the noted references, the panel consensus was to add liposomal doxorubicin/bevacizumab to the list of preferred recurrence therapies for platinum-resistant disease.</td>
<td>13</td>
<td>Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32(13):1302-1308.</td>
</tr>
<tr>
<td></td>
<td>Based on the data in the noted references, the panel consensus was to add paclitaxel (weekly)/bevacizumab to the list of preferred recurrence therapies for platinum-resistant disease.</td>
<td>15</td>
<td>Liu JF, Cannistra SA; Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer. J Clin Oncol 2014;32(13):1287-1289.</td>
</tr>
<tr>
<td></td>
<td>Based on the data in the noted references, the panel consensus was to add topotecan/bevacizumab to the list of preferred recurrence therapies for platinum-resistant disease.</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>